Centro Hospitalar Universitario Lisboa Central E.P.E.

Research at the site explores innovative approaches to prevent recurrent cerebrovascular events. A study evaluates whether milvexian can lower the risk of Acute Ischemic Stroke and high‑risk transient ischemic attacks.

• Milvexian efficacy in stroke prevention
• Safety profile after acute ischemic events

Centro Hospitalar Universitario Lisboa Central is advancing cardiovascular care through these trials.

A rare genetic skin condition, Netherton syndrome, is being investigated to determine if the antibody spesolimab improves disease control.

• Spesolimab response in Netherton syndrome
• Assessment of safety in hereditary dermatologic disorder

The Neurology Department supports this research at Centro Hospitalar Universitario Lisboa Central.

Patients with vision loss from macular edema secondary to retinal vein occlusion are receiving a higher dose of the anti‑VEGF agent aflibercept to assess visual improvement and safety.

• Aflibercept dosing comparison for macular edema
• Best‑corrected visual acuity outcomes

This ophthalmic investigation is conducted at Centro Hospitalar Universitario Lisboa Central.

The department evaluates novel biologics for severe allergic skin disorders. Trials test rocatinlimab in adolescents with moderate‑to‑severe atopic dermatitis and tralokinumab for atopic hand eczema.

• Rocatinlimab safety in adolescent atopic dermatitis
• Tralokinumab efficacy in hand eczema

These immune‑targeted studies are part of the research portfolio at Centro Hospitalar Universitario Lisboa Central.

Long‑term safety of the oral agent tolebrutinib is being monitored in adults with relapsing and progressive multiple sclerosis, aiming to expand therapeutic options for this chronic condition.

• Tolebrutinib tolerability in multiple sclerosis
• Impact on disease progression

The Neurology team at Centro Hospitalar Universitario Lisboa Central leads this multiple sclerosis research.

A pediatric study adds selexipag to standard therapy for children with Pulmonary Arterial Hypertension, seeking to delay disease progression and improve outcomes.

• Selexipag as add‑on in pediatric PAH
• Comparison with placebo in disease delay

This respiratory investigation is coordinated through Centro Hospitalar Universitario Lisboa Central.

Multiple trials target atopic skin inflammation, including a phase 3b study of tralokinumab for moderate‑to‑severe atopic hand eczema and a safety assessment of rocatinlimab in adolescent atopic dermatitis.

• Tralokinumab for hand eczema severity
• Rocatinlimab tolerability in adolescents

These skin‑focused studies are conducted at Centro Hospitalar Universitario Lisboa Central.

An European randomized trial evaluates a therapeutic approach for confirmed Monkeypox infection, measuring time to resolution of cutaneous and mucosal lesions.

• Efficacy against monkeypox lesions
• Safety compared with control group

The virology component of this research is hosted by Centro Hospitalar Universitario Lisboa Central.